Taysha Gene Therapies Profit Margin

Taysha Gene Therapies (TSHA) currently reports a profit margin of -2728.04% as of June 2026. That compares with -1144.97% in the prior-year period — down 138.3% year over year. That is below the Healthcare sector average of 13.45%. Use the charts on this page to explore Taysha Gene Therapies's profit margin history and peer comparisons.

Taysha Gene Therapies's profit margin decreased from -1144.97% to -2728.04% — a 138.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Taysha Gene Therapies's profit margin of -2728.04% is lower than the Healthcare sector average of 13.45%. That is roughly 20386.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Taysha Gene Therapies's current -2728.04% should be judged against Healthcare norms (sector average: 13.45%) and against TSHA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2728.04%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.45%. From there, open related valuation or income-statement pages for Taysha Gene Therapies, and consider following TSHA for alerts when major investors trade the stock.